Pulmonary Arterial Hypertension
New Approaches to Pulmonary Arterial Hypertension Management
Speakers: Victor F. Tapson, MD, FCCP, FRCP, Professor of Medicine, Pulmonary Critical Care Medicine
Duration: 60 minutes
Presented on: May 24, 2017
Victor F. Tapson, MD, FCCP, FRCP
Victor F. Tapson, MD, FCCP, FRCP
Professor of Medicine, Pulmonary Critical Care MedicineVictor F. Tapson, MD, FCCP, FRCP, is professor of medicine, director of the Clinical Research for the Women’s Guild Lung Institute and the Venous Thromboembolism and Pulmonary Vascular Disease Research Program, and associate director of the Pulmonary and Critical Care Division at Cedars-Sinai Medical Center in Los Angeles, California. Dr Tapson has devoted his career to patient care, research, and teaching in pulmonary hypertension and pulmonary embolism. He’s served on the steering committees for the World PH Guidelines, started the first PAH journal, Advances in PH, and served as worldwide PI or co-PI for several venous thromboembolism registries. He is currently PI for the OPTALYSE PE, BiO2 IVCF and FLARE clot-extraction studies, and the TAFIa clinical trial in acute PE.
New Approaches to Pulmonary Arterial Hypertension Management Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC
ACKNOWLEDGEMENT This activity is supported by an independent educational grant from Actelion Pharmaceuticals US, Inc. TUITION Complimentary
ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION Live Internet Activity The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Enduring Material The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DATE OF RELEASE/EXPIRATION Live Activity Wednesday, May 24, 2017 from 11:00am – 12:00pm EDT March 29, 2017 from 11:00 AM EST – 12:00 PM EST (Supplementary session)
Enduring Material The enduring material will be available from May 24, 2017 to May 24, 2018.
LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to:
• Diagnose pulmonary arterial hypertension at earlier stages of the disease • Assess the clinical safety and efficacy data for approved PAH drug treatment regimens with respect to impact on morbidity and mortality • Utilize combination therapy as appropriate in patients with pulmonary arterial hypertension at earlier stages of the disease
TARGET AUDIENCE This activity is intended for cardiologists, pulmonologists, hospitalists, internists, primary care clinicians, nurses, nurse practitioners, pharmacists and other health care professionals who manage patients with PAH.
ESTIMATED TIME TO COMPLETE This activity consists of one session which should take approximately 1 hour to complete.
METHOD OF PARTICIPATION There are no fees to participate in this activity. To participate in the activity, go to http://www.cardiocarelive.com/. To receive credit, participants must (1) read the CME information, including the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. This activity consists of three sessions, each of which will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.
HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
DISCLOSURE OF CONFLICTS OF INTEREST Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship: Victor F. Tapson, MD Director, Venous Thromboembolism and Pulmonary Vascular Disease Research Director, Clinical Research Women’s Guild Lung Institute Associate Director, Pulmonary Critical Care Medicine Cedars-Sinai Medical Center
Grant/Research Support: Actelion Pharmaceuticals US, Inc., Arena Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Bayer A.G., United Therapeutics Corporation Consultant: Actelion Pharmaceuticals US, Reata Pharmaceuticals, Inc., Bayer A.G., United Therapeutics Corporation Speaker’s Bureau: Actelion Pharmaceuticals US, Bayer A.G.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner Reported Financial Disclosure Hamsa Jaganathan, PhD Medical Director PlatformQ Health Education, LLC
The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose. The following PlatformQ Health Education, LLC planner, Elizabeth del Nido, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable): This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT INFORMATION Accreditation Support: Please contact the Postgraduate Institute for Medicine at www.pimed.com.
Technical Support: For any technical issues or issues with your CME Certificate, please contactCardioCareLive at 877-394-1306, or at Support@CardioCareLive.com.